COLLEGIUM PHARMACEUTICAL, INC (COLL) saw its loss widen to $23.08 million, or $0.79 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $15.65 million, or $0.68 a share.
Revenues for the quarter were $2.17 million. The company has not recorded any revenues for the previous year period. Gross margin for the quarter was at 82.92 percent.
Operating loss for the quarter was $23.18 million, compared with an operating loss of $15.59 million in the previous year period.
"During the first quarter, we are encouraged by the continued adoption of Xtampza ER and the positive reception by both prescribers and payors. We expect that this progress will continue to accelerate as we broaden our commercial initiatives," said Michael Heffernan, Collegium's chief executive officer.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]